Leave No Cancer Behind: the Conformal Hypofractionation Era and Head and Neck Cancer

While much of the focus has shifted toward optimizing outcomes for the more favorable human papillomavirus (HPV)–associated head and neck squamous cell carcinomas (HNSCC), outcomes for HPV-negative HNSCCs have remained static for more than 2 decades. Concurrent systemic therapies beyond cisplatin have failed to deliver improved disease control, although the door remains open for emerging agents and adjuvant therapies. Riding a wave of noninferiority trials, radiation oncologists have adopted hypofractionation in a variety of other cancers.